The Board of Directors of the Society of Infectious Diseases Pharmacists (SIDP) is pleased to announce the availability of funding for an Infectious Diseases Pharmacotherapy Residency for the period of **July 2019 through June 2020**. This residency award will be partially supported by BioMerieux and Allergan Inc.

The intent of this funding is to foster the development and/or expansion of new advanced training opportunities for pharmacists committed to the practice area of infectious diseases pharmacotherapy. Applications will **only be considered** from programs developing a new infectious diseases specialty training program in 2019 or established programs expanding the number of available infectious diseases resident positions.

SIDP will provide funding to support the resident salary for one year plus fringe benefits and will include $1,500 travel support to attend the SIDP annual meeting (**total grant not to exceed $60,000**). The program will be responsible for any additional funding required to support resident salary plus fringe benefits.

SIDP members who have a) received an SIDP Residency Grant award as either Residency Director in the past, or b) served as preceptor at the same or affiliated institution in the past three years, or c) current members of the SIDP Board of Directors are **ineligible** for these awards.

Members awarded funding must send a copy of the letter of acceptance from the resident plus CV and proof of PGY1 residency training or summary of pharmacy practice experiences of the resident applicant to SIDP Headquarters no later than **June 26, 2019** or the award will be rescinded. A midpoint and final report of the resident’s activities (rotations including stewardship activities, key presentations, and longitudinal research) will be also required.

**Completed applications should be electronically submitted as follows:**

Applications should be entered online at the SIDP website ([www.sidp.org](http://www.sidp.org)) using the resident award application form. The RPD cover letter, letters of support (2) and curriculum vitas (up to 4) should be converted to a single PDF file and uploaded. Other information will be directly inserted on the web form. Questions regarding submission may be submitted to SIDP Secretary/Treasurer, Emily Heil, PharmD (eheil@rx.umaryland.edu). **Proposals must be submitted no later than 5 PM EST on September 7, 2018.** Applications submitted after this deadline will not be considered. The Board of Directors will make decisions on the applications no later than **September 30, 2018**.

For residencies, applicants are encouraged to refer to the ASHP Educational Outcomes, Goals, and Objectives for Postgraduate Year Two (PGY2) Pharmacy Residencies in Infectious Diseases. These guidelines were prepared by ASHP in collaboration with ACCP and SIDP and endorsed by the SIDP Board of Directors. SIDP supports the utility of the ASHP Educational Outcomes, Goals, and Objectives for PGY2 Pharmacy Residencies in Infectious Diseases for any residency funded by SIDP.
Criteria for Award Evaluation

Award Recipient:
1. Is a Active member of SIDP at the time of application and not currently serving on the Board of Directors.
2. Has completed advanced training in ID pharmacotherapy (PGY2 residency or fellowship) or has at least 3 years of experience as an active clinical practitioner or researcher in ID pharmacotherapy.
3. Has experience in precepting or directing postgraduate training.

Institution:
1. Is capable of providing a full range of training experiences which may include inpatient care, outpatient care, antimicrobial stewardship, pediatrics, HIV, microbiology laboratory, infection control, and a longitudinal experience. Antimicrobial stewardship need not be the focus of a program, but should be an important element.
2. Has administrative support of the residency training program as indicated in an accompanying letter of support.
3. Has adequate space and resources identified to support resident training.
4. Has existing infrastructure to support a specialty training program.

Residency Candidate:
1. Possesses a Doctor of Pharmacy degree from an ACPE-accredited college of pharmacy.
2. Has completed a PGY1 Residency, is currently in training in a PGY1 residency program that will be completed before the start of this program, or has equivalent pharmacy practice experience.

Residency Program:
Follows the updated guidance of the ASHP Accreditation Standards for Infectious Diseases PGY2 Pharmacy Residency Programs. Available at: https://www.ashp.org/Professional-Development/Residency-Information/Residency-Program-Directors

Required Elements for Application
1. A letter of application from individual who will serve as residency director. The letter should include the following components: rationale for development of a new program or expansion of a new position, recruitment strategy, preceptor and institution qualifications (brief), and program goals. Please briefly explain the plan for the residency if not selected for funding in this cycle. The letter should be limited to a 2 page maximum.
2. A letter of support from Director of Pharmacy Services or administrative equivalent at the primary facility where residency training will occur.
3. A letter of support from a physician champion (eg Chief of Infectious Diseases or antimicrobial stewardship physician) who will work with the resident during the training program.
4. A current curriculum vitae for the program director and for up to three additional individuals who will serve as preceptors during the training experience.
5. A description of the institution where primary training will occur. It is recommended to include a description of the following: pharmacy department structure; pharmacy practice model; infectious diseases services infrastructure; service lines/patient population. Responses should be limited to 500 words or less.
6. A description of resident opportunities in teaching/academics, research and professional/community service. Responses should be limited to 750 words or less.
7. A description of rotation experiences. Responses should be limited to 500 words or less

Revised 7/11/2018